Narcolepsy

In the phase 1 trial, the 2.5 mg dose of ORX750 significantly improved wakefulness, restoring normal sleep latency to 32 minutes compared to placebo.

Vibrance-2 is a double-blind, placebo-controlled trial with 80 participants, assessing three doses of ALKS 2680 over eight weeks

The double-blind, single-dose, 5-period crossover study is expected to include approximately 40 patients with narcolepsy type 1 to test 3 dose strengths of E2086.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on care of idiopathic hypersomnia.

The therapeutic head for Clinical Development Neuroscience at Jazz Pharmaceuticals discussed how sodium oxybate has evolved over the years and the educational aspects of cardiovascular implications patients and clinicians should be aware of. [WATCH TIME: 3 minutes]

The therapeutic head for Clinical Development Neuroscience at Jazz Pharmaceuticals provided clinical insight on a new study evaluating the effect of switching from high- to low-sodium oxybate on blood pressure. [WATCH TIME: 4 minutes]

Pitolisant is the first and only drug in the class of antagonist/reverse agonists of the histamine H3 receptor for the treatment of patients with narcolepsy.

Across both the primary and secondary end points, treatment with TAK-861 resulted in significant improvements in symptom severity among patients with narcolepsy type 1.

Ron Grunstein, MD, PhD, head of Sleep and Circadian Research at the Woolcock Institute of Medical Research, provided commentary on early, promising data regarding investigational agent ALKS 2680 in patients with narcolepsy type 1.

The pediatric neurologist and sleep medicine specialist at Geisinger Medical Center discussed a presentation from SLEEP 2024 highlighting the impacts of narcolepsy and how patients try to mitigate their symptoms. [WATCH TIME: 5 minutes]

Drs Thorpy, Dogan, Doghramji, and Kushida share clinical pearls for primary care providers who are taking care of patients with narcolepsy.

Experts in sleep medicine the ongoing studies and new treatments for narcolepsy

Drs Thorpy, Dogan, Doghramji, and Kushida talk about treatment holidays in narcolepsy.

Alkermes embarks on the phase 2 Vibrance-1 trial to evaluate the safety and efficacy of ALKS 2680 against placebo as a once-daily treatment for narcolepsy type 1.

Experts in sleep medicine discuss the criteria for changing treatment in narcolepsy.

Alberto Ramos, MD, FAAN, director of the Sleep Disorders program at the University of Miami, provided commentary on a session chaired at AAN 2024 assessing the diagnostic criteria and treatment options of parasomnias in adults.

Drs Thorpy, Dogan, Doghramji, and Kushida talk about the use and uptake of newer narcolepsy treatments in clinical practice.

Experts in sleep medicine share their knowledge on abuse and dependency potential with newer narcolepsy treatment.

Sleep medicine experts discuss the treatment of narcolepsy in pregnancy.

Drs Thorpy, Bogan, Doghramji, and Kushida discuss combination therapy and patients with complex narcoleptic disease.

Drs Thorpy, Dogan, Doghramji, and Kushida detail which medications to use in various patients with narcolepsy.

Experts in sleep medicine summarize the available safety data on various agents for the treatment of narcolepsy.

Drs Thorpy, Dogan, Doghramji, and Kushida review the various treatment classes for narcolepsy.

Sleep medicine experts discuss how to select the appropriate treatment for narcolepsy.

ALKS 2680, an investigational orexin 2 receptor agonist, showed promise for improving sleep latency in patients with narcolepsy type 2 and idiopathic hypersomnia in a phase 1b study.

The newly initiated phase 3 trial follows a successful phase 2 study where treatment with pitolisant resulted in greater improvement on the Epworth Sleepiness Scale for Children and Adolescents than placebo.

The presence of a sleep disorder was associated with a nearly 2-fold increase in the risk of increased health care utilization, with specific odds associated with individual sleep disorders.

Experts in sleep medicine talk about the effect narcolepsy can have on the quality of life.

Sleep medicine experts review the contributing factors and comorbidities seen in patients with narcolepsy.

The medical director of the Center for Sleep Medicine at Weill Cornell Medicine talked about the importance of sleep health in modern life with the increasing prevalence of sleep disorders such as narcolepsy in the United States. [WATCH TIME: 5 minutes]